Skip to content

Study · Case report or series · n = 1 · 2026

3 results

Nonarteritic anterior ischemic optic neuropathy after rapid weight loss during semaglutide therapy: a case report.

Cho CH, Kim WJ

Korean journal of family medicine18 Sept 2026

PMID42773534 (opens in a new tab)PMCIDPMC13617292 (opens in a new tab)DOI10.4082/kjfm.26.0135 (opens in a new tab)PepBankPUB-42773534
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    A 42-year-old man developed NAION that was temporally associated with semaglutide therapy and rapid weight reduction.

    In plain wordsOne man developed an eye nerve problem (NAION) during semaglutide therapy and rapid weight loss; a single case cannot show cause.

    Peptide
    Semaglutide
    Outcome
    Not applicableNonarteritic anterior ischemic optic neuropathy (NAION)
    Study

    n = 1

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    He was diagnosed with NAION, which was temporally associated with semaglutide therapy and rapid weight reduction.
    2 context sentences
    Summary · context
    A 42-year-old man presented with acute visual disturbance in the right eye after losing approximately 40 kg over 2 months while receiving semaglutide (Wegovy) for obesity treatment.
    Summary · context
    Herein, we report a case of NAION that developed after marked, rapid weight loss during semaglutide therapy in a young man with multiple vascular risk factors.
  2. 02HumanCase report or seriesEfficacy outcome

    A 42-year-old man lost approximately 40 kg over 2 months while receiving semaglutide for obesity.

    In plain wordsOne man lost about 40 kg in 2 months while taking semaglutide for obesity.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss during semaglutide therapy
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight loss
    ≈ 40 kg
    2 months

    Source sentences

    Summary
    A 42-year-old man presented with acute visual disturbance in the right eye after losing approximately 40 kg over 2 months while receiving semaglutide (Wegovy) for obesity treatment.
    1 context sentence
    Summary · context
    Herein, we report a case of NAION that developed after marked, rapid weight loss during semaglutide therapy in a young man with multiple vascular risk factors.

Studies that did not test the peptide alone1

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 03HumanNot a test of Semaglutide aloneCase report or seriesOther

    After semaglutide was stopped and intravenous methylprednisolone was given, optic disc edema resolved at 6 months but the visual field defect persisted.

    In plain wordsAfter semaglutide was stopped and steroids were given, the eye swelling went away but the vision loss remained.

    Peptide
    Semaglutide
    Outcome
    MixedCourse after semaglutide discontinuation and methylprednisolone
    Study

    n = 1

    Outcome group
    Neuroprotection · Eye

    Source sentences

    Summary
    At 6 months, the optic disc edema had resolved, leaving mild disc pallor, though the visual field defect persisted.
    1 context sentence
    Summary · context
    Semaglutide was discontinued, and high-dose intravenous methylprednisolone was administered.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.